Clinical Trials
14 trialsNCT06238479 2026-05-22
EXCEED
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06465069 2026-05-22
NEXUS-01
Eli Lilly and Company
Phase 1 Recruiting
NCT01552434 2026-05-15
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT07558447 2026-04-30
CHEMOVES
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase NA Recruiting
NCT03420963 2026-03-20
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05192837 2026-02-27
PORTICO
Luzerner Kantonsspital
Phase NA Terminated
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT02783300 2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1 Completed
NCT06827639 2025-02-14
FUTURE
Assistance Publique Hopitaux De Marseille
Not yet recruiting
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT03245788 2019-04-08
Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study
Stanford University
Phase NA Completed
NCT02543645 2018-04-30
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
Phase 1 Terminated
NCT03010813 2018-02-06
A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery
Chinese University of Hong Kong
Phase NA Completed